Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 7/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506546 | 0.83 | ALDH1A1 (0.36) | ALDH1A1KDM4EALOX15ALOX5SMN1; SMN2 | |
| SCHEMBL506603 | 0.83 | L3MBTL1 (0.37) | ALDH1A1KDM4EALOX15ALOX5TSHR | |
| SCHEMBL14431862 | 0.80 | KDM4E (0.31) | ALDH1A1KDM4EALOX15 | |
| SCHEMBL765342 | 0.72 | — | — | |
| SCHEMBL9019517 | 0.71 | PTGS1 (0.38) | ALDH1A1KDM4EALOX15TSHRSMN1; SMN2 | |
| SCHEMBL4546377 | 0.67 | GABRA1 (0.33) | ALOX5TSHRHPGDBLMNPC1 | |
| SCHEMBL827163 | 0.67 | — | — | |
| SCHEMBL1343960 | 0.67 | — | — | |
| SCHEMBL9925244 | 0.65 | — | — | |
| SCHEMBL7454283 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| US-10434052-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | ALDH1A1 985/4885KDM4E 656/4885ALOX15 398/4885 |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | ALDH1A1 985/4885KDM4E 656/4885ALOX15 398/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | ALDH1A1 1485/4885KDM4E 417/4885ALOX15 848/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | ALDH1A1 1019/4885KDM4E 3701/4885ALOX15 1633/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | ALDH1A1 1093/4885KDM4E 3614/4885ALOX15 1530/4885 |
| US-10434052-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | GLA, DGKA, DGKG | ALDH1A1 1129/4885KDM4E 527/4885ALOX15 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.